The USPTO Issues Patent Covering Precision Biologics’ NEO-201 for its Methods of Targeting Treg Cells
Shots:
- The USPTO has granted patent no. US 12,037,410B2 to the company’s NEO-201 (humanized IgG1 mAb), being evaluated under P-II study across the US
- The patent covers NEO-201's ability to bind, isolate, detect & destroy Treg cells through complement-mediated cytotoxicity (CDC) in vitro. It also covers therapeutic methods & combination therapies with other anti-cancer agents
- The above results formed the basis of P-II trial assessing NEO-201 + Keytruda for solid tumors resistant to checkpoint inhibitors & recruiting NSCLC, head & neck cancer, endometrial cancer and cervical cancer patients. P-II data showed reduced Treg cells & gMDSCs in PBMCs, stabilizing the disease
Ref: PR Newswire | Image: Precision Biologics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
